Shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) hit a new 52-week low during trading on Thursday . The stock traded as low as $12.17 and last traded at $12.93, with a volume of 20392 shares traded. The stock had previously closed at $12.88.
Several analysts have recently commented on ZEAL shares. Zacks Investment Research downgraded shares of ZEALAND PHARMA/S from a “hold” rating to a “sell” rating in a research report on Thursday, March 15th. ValuEngine raised shares of ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $24.75.
The stock has a market capitalization of $396.08 million and a P/E ratio of -8.78.
Several hedge funds have recently made changes to their positions in ZEAL. Farallon Capital Management LLC grew its position in shares of ZEALAND PHARMA/S by 33.1% during the 1st quarter. Farallon Capital Management LLC now owns 865,000 shares of the company’s stock worth $12,992,000 after buying an additional 215,000 shares during the period. Millennium Management LLC lifted its holdings in shares of ZEALAND PHARMA/S by 438.1% in the 1st quarter. Millennium Management LLC now owns 170,844 shares of the company’s stock worth $2,566,000 after purchasing an additional 139,092 shares in the last quarter. Fred Alger Management Inc. bought a new position in shares of ZEALAND PHARMA/S in the 4th quarter worth $544,000. AWM Investment Company Inc. lifted its holdings in shares of ZEALAND PHARMA/S by 8.1% in the 4th quarter. AWM Investment Company Inc. now owns 302,901 shares of the company’s stock worth $4,119,000 after purchasing an additional 22,700 shares in the last quarter. Finally, OLD Mission Capital LLC bought a new position in shares of ZEALAND PHARMA/S in the 4th quarter worth $215,000. 10.93% of the stock is owned by institutional investors.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.